[CAN WE USE ASPIRIN AS A PRIMARY PREVENTION FOR CARDIOVASCULAR DISEASE?]

Area of Science:

• Cardiology
• Preventive Medicine
• Clinical Trials

Context:

• Aspirin has been historically considered for primary prevention of cardiovascular disease (CVD).
• Recent clinical trials indicate that aspirin's efficacy for primary CVD prevention is contingent upon individual risk factors.
• Current guidelines reflect a nuanced approach based on age and calculated CVD risk.

Purpose:

• To summarize current evidence and guidelines regarding aspirin use for primary prevention of cardiovascular disease.
• To delineate age-specific recommendations for aspirin initiation in CVD primary prevention.
• To inform clinical decision-making based on updated research findings.

Summary:

• Aspirin is recommended for primary prevention of CVD events in individuals aged 40 to 59 with a 10% or greater 10-year CVD risk.
• For individuals aged 60 years and older, the benefits of aspirin for primary CVD prevention are less clear, and it is not generally recommended.
• These recommendations are based on recent clinical trial data and updated guidelines, such as those from the USPSTF.

Impact:

• Facilitates evidence-based prescribing of aspirin for primary CVD prevention.
• Reduces potential harm from unnecessary aspirin use in older adults.
• Contributes to personalized medicine approaches in cardiovascular health.